我武生物(300357.SZ)業績快報:2021年度淨利潤升21.46%至3.38億元
格隆匯2月11日丨我武生物(300357.SZ)發佈2021年度業績快報,實現營業總收入8.08億元,同比增長26.95%;歸屬於上市公司股東的淨利潤3.38億元,同比增長21.46%;扣除非經常性損益後的歸屬於上市公司股東的淨利潤3.16億元,同比增長20.83%;基本每股收益0.6459元。
報吿期內,在董事會的領導及管理層、全體員工的共同努力下,公司扎扎實實開展各項工作,實現了較快的經營業績增長。此外,我國脱敏診療市場規模持續擴大,舌下免疫治療作為變應性鼻炎的一線治療方法,臨牀接受度和認可度越來越高。公司依託專業的學術營銷團隊,通過多層次的學術會議加大產品推廣力度,市場有效需求不斷增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.